chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She woke up with a fever; Bad headache; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Bad headache) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 039k20A) for COVID-19 vaccination.     No medical history reported.  Concomitant products included LOSARTAN, ATORVASTATIN, ESCITALOPRAM OXALATE (LEXAPRO) and AMITRIPTYLINE for an unknown indication.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Feb-2021, the patient experienced HEADACHE (Bad headache). At the time of the report, HEADACHE (Bad headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100 (Inconclusive) Fever of 100.         Treatment information was not provided.  The patient received both scheduled doses of mRNA-1273 prior to the events therefore, action taken with the drug in response to the event is not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 04-Feb-2021: Follow-up received included updated verbatim (low fever and very bad headache over eyes, lasted half a day).
the patient died from the flu shot; Initial information received on 19-Oct-2020 regarding an unsolicited valid serious case received from a consumer via social media.  This case involves a male patient (unknown age) who died (death) after receiving INFLUENZA VACCINE.  Medical history, medical treatments, vaccinations, family history and concomitant medications were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient died (death), (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  Date of death was not reported. It was unknown at the time of reporting if an autopsy was done and the cause of death was not reported.  Information on the batch number was requested.; Sender's Comments: A case was reported from social media, which involved a male patient of an unknown age who died after vaccination with INFLUENZA VACCINE (unknown manufacturer). Time to onset was unknown. Additional information regarding patient's relevant medical history, health condition at time of vaccination, concomitant medication and Laboratory tests, autopsy results for cause of death is needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.; Reported Cause(s) of Death: Death NOS
Moderna COVID-19 Vaccine EUA Dose 1  One hour after receiving injection- light headed, dizzy, trembling, hot flashes, extreme nausea, confusion, hard time speaking, skin numbness and tingling at injection site and on face/neck/arms. Took Benadryl (diphenhydramine). Acute symptoms dissipated after a couple hours. Continued to feel dizzy when standing/walking. Confusion/short term memory loss of entire afternoon evening (told by others- can?t remember actions, repeating myself and not remembering, can?t remember conversations). About two hours after injection, extreme muscle pain in left arm. Couldn?t lift or move arm and hurt even when not moving, took 440mg naproxen. Brought pain down to a more normal feeling of post shot soreness.
sore throat; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat). At the time of the report, OROPHARYNGEAL PAIN (sore throat) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were reported.   Reporter did not allow further contact
Father of client calls stating that his son is broke out in a rash covering his entire body that looks similar to chickenpox.  Advised to take client to see his pediatrician.  Client returns call and states that pediatrician indicated that rash was an allergic reaction to vaccines administered 1 week ago and prescribed Benadryl.
fever, lethargy w/in 24hr local erythema, warmth (4cm) tenderness;
Leg spasms; She has a patient who is pregnant with her first child. She had the second dose of the vaccine on April 1st.; Just 2 days after she had leg spasms then it led to being paralized; she had leg spasms then it led to being paralized. It spread through her whole body, even her stomach; She is now a transverse/ have Transverse mylighttis as well; she had leg spasms then it led to being paralized. It spread through her whole body, even her stomach; This is a spontaneous report from a Pfizer sponsored program  support from a non contactable consumer.  A 37-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 01Apr2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 on unknown date. The patient was pregnant with her first child. She had the second dose of the vaccine on 01Apr2021. Just 2 days after she had leg spasms then it led to being paralized. It spread through her whole body, even her stomach. She was put into the hospital and she was now a transverse and was going to hospice. She was only 37 years old and the caller wanted to know what happened to other people who have transverse mylighttis as well. The outcome of all events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Information has been received from a medical assistant referring to multiple unspecified patients of unknown age and gender. The patients' concurrent condition, medical history and concomitant medication were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of ROTATEQ (dose was unknown, lot # L046318 with expiration date 28-SEP-2017, and lot # L039640 with expiration date 24-AUG-2017) orally. The vaccines were exposed to temperature excursion of 57.0 degrees Fahrenheit (F) for 1 hour and 50.8 degrees Fahrenheit (F) for 1 hour. No previous temperature excursion was reported. Data logger was involved. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
At 48 hours (12/13/21), developed left sided flank pain. Progressed to severe sub-sternal chest pain on 12/15/21 prompting ED visit. Chest pain radiated to neck, worse with deep inspiration, relieved with sitting forward. Chest pain associated with diaphoresis and vomiting secondary to pain. EKG changes: new T wave inversions V4-V6, and I and II Bedside echo without clinically significant effusion. Troponin negative x 2 and discharged home with presumptive diagnosis of pericarditis/myocarditis.
1-16-16 pt noted left arm swelling and itching. Pt. in clinic 1-18-16 declined to wait for no show to see provider app 1-19-16 with MD.
The following patient came in today for a Pfizer IM vaccine. Both tech and I explained to the patient the correct area of deltoid administration is two fingers down and above the armpit, in that triangle area. The patient insisted on us doing it lower to "avoid the tendons" - I explained that if I did it any lower it may actually hit tendons/nerves. I indicated with my glove where I would give the vaccine, which is in the correct area, and the patient said "that was acceptable" - however, when I gave it the patient said "it hurt and it was not in the correct muscle." DPM and PCP pharmacists have been notified and suggested a report to be made for documentation purposes. Tried to reach the patient but unable to reach by phone.
190 patients (9 different lot numbers) received a vaccine past the beyond used by date; No Adverse Event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date).    No concomitant medication was reported. 190 patients (9 different lot numbers) received a vaccine past the beyond used by date. It was unknown if patient received any other vaccines in the 4 weeks prior to the COVID-19 vaccine administration. No treatment medication was reported. This case pertains to the 71st patient of the total 190 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-704335 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704335:Master case
7 x 3 cm erythematous rash on (L) thigh, 1 x 1 cm on (R) thigh - symptoms appeared 12 hours after vaccinations.
Blood clot that resulted in stroke symptoms; transported via ambulance; administered clot busting drug; hospitalized for three days, and released.
Patient passed out, slight convulsions, blurred vision, general body weakness. Vaccine administered at 11:41am, reaction at 11:44am.
Bad Headache; lead on cough; pressure in chest; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 23Aug2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "2 stents", start date: 15Jan2019 (ongoing); "Gall stones", start date: 2016 (unspecified if ongoing); "Cholecystectomy", start date: 2016 (unspecified if ongoing). Family history included: "Coronary artery disease", start date: 27Nov2012 (ongoing); "quintuple bypass", start date: 27Nov2012 (unspecified if ongoing). Concomitant medication(s) included: ASPIRIN [ACETYLSALICYLIC ACID] taken for cardiovascular disorder, start date: 2012 (ongoing); METOPROLOL TARTRATE taken for cardiovascular disorder, start date: 2012 (ongoing); ISOSORBIDE MONONITRATE taken for cardiovascular disorder, start date: 2014 (ongoing). Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, LOT: FA7484, EXPIRATION DATE: 01Sep2021). The following information was reported: HEADACHE (non-serious) with onset 24Aug2021, outcome "unknown", described as "Bad Headache"; COUGH (non-serious) with onset 24Aug2021, outcome "unknown", described as "lead on cough"; CHEST DISCOMFORT (non-serious) with onset 24Aug2021, outcome "unknown", described as "pressure in chest".  Follow-up attempts completed. No further information is expected. lot/batch number is not available despite the follow-up attempts made.
Pt presented with rash on left thigh with surrounding erythema measuring 16 cm x 17 cm and blanching rash appeared day after injection. Motrin-cold compresses. Benadryl 6 x 3 days for MD.
fever, chills, HA, vomiting, diarrhea, chest tightness, SOB, nonproductive cough; received 1000 mg acetaminophen, GI cocktail, liter ND, liter LR, zofran on discharged, mild tacyhpnea with accessory muscle usage (minimal); abdominal tenderness in epigastric area,
dizziness; weakness; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness) and ASTHENIA (weakness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (dizziness) and ASTHENIA (weakness). At the time of the report, DIZZINESS (dizziness) and ASTHENIA (weakness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment information was reported.   Reporter did not allow further contact
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 01/06/21pfizer,Lot#EL3246 2nd dose: 01/27/21,Pfizer,Lot# EL9262 Diagnosed covid positive:07/29/21 Symptom onset:07/29/21 Exposure:WORK Symptoms:Cough, sore throat.
6-20-11 2-3cm induration Rt upper arm at inj site, erythema, warmth. 6-22-11 6.5 x 2.5cm induration - Rt upper arm at inj. site, erythema, warmth, pain, joint pain. Sed rate 82, Sodium 128. 6-24-11 Sed rate 98, Sodium 128 - using walking/wheelchair x 2 days. 6-28-11 ecchymosis 2" diameter - central firmness with erythema, Sed rate 78, Sodium 129.
Narrative:  06/15 COVID J&J vaccine #1 or 1 from non-agency hospital 06/23 Patient seen in non-agency emergency dept w/ cc "reaction to COVID SHOT" 07/01 Patient seen in non-agency emergency dept w/ cc "ear pain" 08/05 Patient seen in non-agency emergency dept w/ cc "right ear pain" 09/01 Patient seen in facility care,  per nurse "facility patient presents to clinic with concerns over right ear issues.  was treated for mrsa to area approximately two weeks ago with oral antibiotics and antibiotic ear drops. per patient, had acute allergic reaction to janssen immunization in 06/2021. has been having skin issues ever since. has sores to earlobe, is swollen, and painful. He states everything started after he had allergic reaction to J&J vaccine. He had skin rashes/swelling/etc. He developed an  infection in right ear. He was treated for MRSA. He feels as though something is  in his right ear although he was told it was just infection in his ear canal. "Rx'd topical hydrocortisone and cephalexin previously. Symptoms resolved until cephalexin stopped. 09/07 Pt seen in facility care with dx cellulitis bilateral; treated w/ doxycycline and topical ofloxacin 11/04 Pt seen in facility care w/ ear pain, some drainage x 3 days, rx'd SMX/TMP, advised to continue hydrocortisone topical 11/17 Pt calls agency and reports finished antibiotic, has been using  hydrocortisone, but reports facial swelling x 3 days, sever ear pain (10 out of 10), episodes of pus draining from ear and rash on outer ear lobe 11/24 Pt seen in non-agency emergency dept w/ cc ear drainage, no further information available
1/29 2nd moderna vaccine around 3:30 pm 1/30 7:30 am had fever (103 F), body aches, headache, dizziness (room spinning), fatigue. Headache is a frontal headache. Severity 5.5/10, aching in quality. Not the worst headache.  1/31 evening started feeling a little better. Fever reduced 2/1 This morning was fever free so she went to work and then started to feel hot. She took her temp at 4:30pm and it was 102 F (oral). She took tylenol which has helped with the fever. She also had a runny nose and abdominal pain this morning which seems to be better now. Noted patient states that her taste sensation is decreased.
Noticed facial drooping on the left side starting on Friday night and symptoms increasing. Went to urgent care on Monday morning. facial drooping increased over the weekend also lift eye was irritated from lack of moister and did not close or blink without extra effort. wore a patch and lubricated over the weekend. Diagnosed as Bellys Palsy at Lander urgent care medical clinic. Prescribed course of prednisone. Also Erythromycin op mgigm oin akor for the left eye and wear a patch until eye will blink and close normally.
Shingles; Rash; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 67-year-old male patient who received Herpes zoster (Shingrix) (batch number JP427, expiry date 15th May 2022) for prophylaxis.   Previously administered products included Zostavax (received Zostavax years ago). Concomitant products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season).   On 26th October 2020, the patient received the 1st dose of Shingrix. On 12th November 2020, 17 days after receiving Shingrix, the patient experienced shingles and rash. The patient was treated with valaciclovir hydrochloride (Valacyclovir). On an unknown date, the outcome of the shingles and rash were recovered/resolved.   It was unknown if the reporter considered the shingles and rash to be related to Shingrix.  Additional information was provided as follows: On 26th October 2020, the patient received 1st dose of Shingrix. On 12th November 2020, the patient experienced rash on the upper part of left arm, which was diagnosed as shingles by the patient's dermatologist. On 8th September 2020, the patient had received a flu shot. The patient had been taking Valacyclovir daily. The reporter consented to follow up.
Information has been received from a consumer concerning a female friend who on an unspecified date was vaccinated with a dose of varicella zoster virus vaccine live. In Sept 2006, she experienced shingles. No further information was provided. There was no product quality complaint involved. Additional information has been requested.
Fatigue, shortness of breathe, ache bones, nausea, soreness, fever and headaches all occurred within 14 to 24 hours
received a double dose of the Moderna COVID19 vaccine; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXTRA DOSE ADMINISTERED (received a double dose of the Moderna COVID19 vaccine) and NO ADVERSE EVENT (No adverse event) in a 2-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (received a double dose of the Moderna COVID19 vaccine) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXTRA DOSE ADMINISTERED (received a double dose of the Moderna COVID19 vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXTRA DOSE ADMINISTERED (received a double dose of the Moderna COVID19 vaccine).    Concomitant drugs were not reported. It was reported that the reporter's daughter received a double dose of the Moderna COVID-19 vaccine. Treatment medications were not provided.   Reporter did not allow further contact
COVID-19 infection symptoms  started in the morning of 03/18/2023. I had chills,  cough , and cold  like symptoms . I tested positive on the same day using the  a home test. On Monday  03/20/2023 I did a telehealth with my doctor after explaining the symptoms to him,  he    then prescribe me with  Paxlovid  for 5 days.  The next Saturday  03/ 25/2023 I tested negative using a home test.
This case was reported by a physician via call center representative and described the occurrence of therapy non-responder in a adult male patient who received ENGERIX B (batch number EB993, expiry date 13th March 2019). Co-suspect products included ENGERIX B (batch number EB993, expiry date 13th March 2019 and ENGERIX B (batch number EB993, expiry date 13th March 2019). On an unknown date, the patient received the 1st dose of ENGERIX B, he 2nd dose of ENGERIX B and the 3rd dose of ENGERIX B. On an unknown date, unknown after receiving ENGERIX B, ENGERIX B and ENGERIX B, the patient experienced therapy non-responder. On an unknown date, the outcome of the therapy non-responder was unknown. It was unknown if the reporter considered the therapy  non-responder to be related to ENGERIX B, ENGERIX B and ENGERIX B. Additional details were provided as follows: The age at vaccination was not reported. The health care professional had a patient who received 3 doses of ENGERIX B and did not develop an immune response, which led to therapeutic response decreased. It was reported that all 3 doses had same batch number, two doses had the same expiry date, third dose was documented as 31st March 2018 but health care professional thought it was a transcription error and should have been the same as the first two doses as 13th March 2019.
Reactive Arthritis. unable to get up , had to crawl.  all joints stiff and severely painful.
24 Mar 04, received my 5th anthrax shot, deployed in June and in July started getting severe headaches and fatigue.  Was given 800mg of Motrin to take to help.  Went to emergency room for severe headache given shot and told to have further testing at home.  Received a cat scan which was abnormal, then an MRI which revealed a lesion on left front brain.  Told to repeat in 3 months.  In meantime, fatigue continued as well as developing back and joint pain.  Was given anti-inflammatories.  Repeated MRI with no change indicated.  Saw a neurologist is recommending treatment for headaches and thought no neurological significance was indicated from the lesion.
Patient currently not experiencing any side effects. Patient wanted bivalent but was given monovalent as a booster instead.
Myalgias; Extreme fatigue; This case was reported by a physician via call center representative and described the occurrence of myalgia in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number T2CS3, expiry date 21st December 2021) for prophylaxis.   Previously administered products included Shingrix (no reaction with 1st dose).   On 1st May 2020, the patient received the 2nd dose of Shingrix. On 1st May 2020, immediately after receiving Shingrix, the patient experienced myalgia and fatigue. On an unknown date, the outcome of the myalgia and fatigue were not recovered/not resolved.   It was unknown if the reporter considered the myalgia and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and since that time she has felt myalgias and extreme fatigue.  No reaction to first dose and no fever. The reporter asked was there any reports of longer duration side effects than the 2-3 days reported in the prescribing information.
pt recv vax & devel an anaphylactic rxn w/disseminated hives;